股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 公司名稱: 華康生物醫學控股有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08622 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | HKD | | 0.01 | HKD | | 10,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 1,000,000,000 | HKD | | 0.01 | HKD | | 10,000,000 | 本月底法定/註冊股本總額： HKD ...

本 聯 合 公 告 僅 供 參 考，並 不 構 成 收 購、購 買 或 認 購 華 康 生 物 醫 學 控 股 有 限 公 司 證 券 之 邀 請 或 要 約，亦 非 於 任 何 司 法 權 區 招 攬 任 何 接 納、投 票 或 批 准。 香港交易及結算所有限公司及香港聯合交易所有限公司對本聯合公告的內容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 聯 合公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔 任 何 責 任。 代 表ANSELME LIMITED 就華康生物醫學控股有限公司之全部已發行股份 提出強制性無條件現金要約及註銷所有尚未行使之購股權 （ANSELME LIMITED及其一致行動人士已擁有或已同意收購者 除 外）的 綜 合 文 件 Anselme Limited之聯席財務顧問 ANSELME LIMITED （於 英 屬 處 女 群 島 註 冊 成 立 之 有 限 公 司） HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED 華康生物醫學控股有限公司 （於開曼 ...

Core Viewpoint - Huakang Biomedical (08622) has appointed Qingtian Capital Limited as an independent financial advisor to provide advice on the offer and acceptance situation to the independent board committee, offer shareholders, and option holders [1] Group 1 - Qingtian Capital Limited has been granted a license to conduct regulated activities under the Securities and Futures Ordinance (Cap. 571) in Hong Kong [1] - The appointment of Qingtian Capital Limited was approved by the independent board committee in accordance with Rule 2.1 of the Takeovers Code [1]

Group 1 - The core announcement is that Huakang Biomedical (08622.HK) has appointed Qingtian Capital Limited as an independent financial advisor to provide advice on the offer and acceptance situation to the independent board committee, offer shareholders, and option holders [1][2] - The appointment of Qingtian Capital has been approved by the independent board committee in accordance with the takeover code rule 2.1 [1] - Huakang Biomedical has resumed trading this morning following the announcement [2]

Core Viewpoint - Huakang Biomedical (08622) has appointed Qingtian Capital Limited as an independent financial advisor to provide advice on the offer and its acceptance status to the independent board committee, offer shareholders, and option holders [1] Group 1 - Qingtian Capital Limited has been granted a license to conduct regulated activities under the Securities and Futures Ordinance (Cap. 571) of Hong Kong, specifically for providing advice on institutional financing [1] - The appointment of Qingtian Capital Limited has been approved by the independent board committee in accordance with Rule 2.1 of the Takeovers Code [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED 華康生物醫學控股有限公司 茲 提 述 華 康 生 物 醫 學 控 股 有 限 公 司（「本公司」）與Anselme Limited於二零二五年 十 月 九 日 聯 合 刊 發 的 公 告，內 容 有 關（其 中 包 括）完 成 買 賣 協 議 及 要 約（「聯合公 告」）。除 文 義 另 有 所 指 外，本 公 告 所 用 詞 彙 與 聯 合 公 告 所 定 義 者 具 有 相 同 涵 義。 董 事 會 欣 然 宣 佈，擎 天 資 本 有 限 公 司，獲 發 牌 從 事 香 港 法 例 第571章證券及期 貨條例下第6類（就 機 構 融 資 提 供 意 見）受 規 管 活 動 之 法 團，已 獲 委 ...

Core Viewpoint - Anselme Limited has increased its stake in Huakang Biomedical (08622) to 51.84% by acquiring 138.672 million shares at an average price of HKD 0.126 per share, totaling approximately HKD 17.47 million [1] Group 1 - Anselme Limited's recent acquisition involved purchasing 138.672 million shares of Huakang Biomedical [1] - The average price per share for this transaction was HKD 0.126 [1] - Following this transaction, Anselme Limited's total shareholding in Huakang Biomedical is approximately 259 million shares [1] Group 2 - The total amount spent by Anselme Limited for this acquisition was around HKD 17.47 million [1] - The new shareholding percentage of Anselme Limited in Huakang Biomedical is 51.84% [1] - The transaction also involved other related parties, specifically Zhou Xun Yong [1]

Core Viewpoint - Anselme Limited has increased its stake in Huakang Biomedical (08622) by acquiring 138.672 million shares at an average price of HKD 0.126 per share, totaling approximately HKD 17.4727 million, resulting in a new holding of about 259 million shares, representing 51.84% ownership [1] Group 1 - Anselme Limited's acquisition of shares occurred on October 9 [1] - The average price per share for the transaction was HKD 0.126 [1] - The total amount spent on the acquisition was approximately HKD 17.4727 million [1] Group 2 - Following the transaction, Anselme Limited's total shareholding in Huakang Biomedical increased to approximately 259 million shares [1] - The new ownership percentage after the acquisition is 51.84% [1] - The transaction involved other related parties, specifically Zhou Xun Yong [1]

Core Insights - Hong Kong Stock Exchange data indicates that on October 9, Huakang Biomedical (08622) shareholders transferred stocks from Qingtian Securities to Jinlifeng Securities, with a transfer market value of HKD 54.8386 million, accounting for 27.74% of the total [1] Group 1 - On October 9, Huakang Biomedical and the offeror Anselme Limited jointly announced a sale and purchase agreement, where the seller Li Jingyang conditionally agreed to sell and the offeror conditionally agreed to acquire all legal and beneficial ownership and rights of the shares (1.387 billion shares), representing approximately 27.71% of the total issued share capital as of the announcement date, for a total consideration of HKD 17.4727 million, equivalent to HKD 0.126 per share [1]

Core Viewpoint - Huakang Biomedical (08622) announced that its shares will resume trading on October 10, 2025, at 9:00 AM [1] Company Summary - The company has made an official announcement regarding the resumption of its stock trading [1]